Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

22.16 +0.46 (+2.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 719,845
Open 22.02
Bid (Size) 22.16 (3,500)
Ask (Size) 22.18 (1,800)
Prev. Close 21.70
Today's Range 21.99 - 22.43
52wk Range 16.52 - 25.14
Shares Outstanding 65,504,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+11.5%
+11.5%
1 Month
-3.6%
-3.6%
3 Month
-2.5%
-2.5%
6 Month
+6.2%
+6.2%
1 Year
+7.6%
+7.6%

More News

Read More
INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals ↗
Via Chartmill
News headline image
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva Inc (NASDAQ:INVA) Screened as a Top Value Stock with Strong Fundamentals ↗
Via Chartmill
INNOVIVA INC (NASDAQ:INVA) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗
Via Chartmill
Innoviva Inc (NASDAQ:INVA) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock ↗
Via Benzinga
News headline image
3 Bargain-Cheap Small Caps Worth a Second Look ↗
Via MarketBeat
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗
Via MarketBeat
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA) ↗
Via Chartmill
News headline image
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks ↗
Via Chartmill
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential ↗
Via Chartmill

Frequently Asked Questions

Is Innoviva, Inc. - Common Stock publicly traded?
Yes, Innoviva, Inc. - Common Stock is publicly traded.
What exchange does Innoviva, Inc. - Common Stock trade on?
Innoviva, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Innoviva, Inc. - Common Stock?
The ticker symbol for Innoviva, Inc. - Common Stock is INVA on the Nasdaq Stock Market
What is the current price of Innoviva, Inc. - Common Stock?
The current price of Innoviva, Inc. - Common Stock is 22.16
When was Innoviva, Inc. - Common Stock last traded?
The last trade of Innoviva, Inc. - Common Stock was at 06/04/26 04:00 PM ET
What is the market capitalization of Innoviva, Inc. - Common Stock?
The market capitalization of Innoviva, Inc. - Common Stock is 1.45B
How many shares of Innoviva, Inc. - Common Stock are outstanding?
Innoviva, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.